NEXT GENERATION PDT
CANCER THERAPY FOR THE 21ST CENTURY
WHO ARE WE?

We are an International Team of dedicated professionals, research scientists and physicians, who have researched and developed a uniquely effective ‘Next Generation PDT’ photosensitizer agent activated by a novel ‘Next Generation PDT’ light bed for the treatment for many forms of solitary, metastatic and of advanced stage cancer. NGPDT’s pioneering discoveries are set to change the face of medicine forever.

BACKGROUND

We, at NGPDT fully embrace the approach that cancer is a systemic condition and requires a non-toxic therapeutic strategy that treats the patient’s entire body. The ability of NGPDT to specifically identify and destroy cancer cells while leaving the rest of the body’s normal cells unharmed is a revolutionary advancement compared to the first generation photodynamic therapy (PDT) and the highly invasive and toxic therapies associated with chemo, surgery and radiation.

Our prime goal is to provide a ‘state of the art’, effective cancer treatment solution and to make the widespread fear of cancer on humanity a thing of the past.

NEXT GENERATION PDT

This long-awaited development brings, PDT (Photodynamic Therapy) to its rightful place, as a preferred cancer therapy for the 21st century.
NEXT GENERATION PDT
CANCER THERAPY FOR THE 21ST CENTURY
NGPDT-NEXT GENERATION PDT

PDT is recognized around the world as a safe, minimally invasive and effective treatment for many forms of cancer.

NGPDT stands for Next Generation PhotoDynamic Therapy. PDT was first discovered about one hundred years ago in Europe, but it was only incorporated into mainstream medicine (by scientists in the US) after eighty years had passed. The photosensitive agent approved by the FDA in 1993 (Photofrin) has been referred to as “first Generation” agent. Subsequent discoveries have led to a dramatically advanced and greatly improved generation of photosensitive agents and medicines: ‘Next Generation PDT’.

PhotoDynamic Therapy is an approved safe and effective treatment for cancer. It’s fundamental success lies in it’s ability to selectively attach to malignant tissue and cause singlet oxygen to be released inside the cancer cell, resulting in either necrosis (immediate cell death) or apoptosis (cells are damaged and will die later) while leaving healthy tissue unaffected. It also can have the effect of reducing the blood supply to tumors and in a patient with a competent immune system can lead to the production of a tumor specific ‘vaccine’ which helps to fight cancer tumors at distance sites throughout the body.
PDT IS RECOGNIZED AROUND THE WORLD

AS A SAFE, MINIMALLY INVASIVE AND EFFECTIVE TREATMENT
Patient is given the ‘NexGenPDT’ photosensitive agent by mouth, a Chlorophyll based formula, which is sensitive to light. The agent selectively accumulates and concentrates in malignant cancer tissue; the patient is then exposed to specific light wave-lengths in the specialized ‘LDS’ Light Bed’. Light activates the NexGenPDT agent on the cancer cells, causing singlet oxygen to be created, which damage and destroy malignant cancer tissue while leaving normal tissue unharmed.

PDT utilizes a photosensitizer which selectively accumulates on diseased tissue followed by the application of specific wavelengths of light while normal tissue is unharmed. Soon after light treatment, the immune system recognizes the fragments of the cancer cells and produces antibodies which helps to control and destroy cancer cells throughout the body.
OUR PRIME GOAL IS TO PROVIDE
A ‘STATE OF THE ART’ TREATMENT SOLUTION
Following light administration tumor cells are damaged or destroyed. Tumor cells (orange).

The specialized ‘LDS’ Light Bed’ activates the NexGenPDT agent on the cancer cells, causing singlet oxygen to be created, which damage and destroy malignant cancer tissue while leaving normal tissue unharmed.

NGPDT technology using red/near infrared (NIR) peaks of absorption and red/NIR light therapy allows whole body treatment as well as therapy for deep seated and advanced tumors (breast, lung, liver, brain, peritoneal).
NIR imaging of breast cancer following Next Generation PDT therapy.

Patient showing improvement of liver cancer following NexGen PDT

Improvement of brain cancer tumors 8 weeks following NexGen PDT
WHAT OPTIONS ARE AVAILABLE?

Patients with cancer who are interested in learning more about this therapy can do the following:

1. If more information, medical or scientific data is desired please see: www.nextgenerationpdt.com and www.pdtbook.com.

2. If patients wish to request the therapy, we need to get an accurate up-to-date assessment of their condition so that an initial decision can be determined of your suitability for the treatment. (the therapy is not suitable for everyone).

3. Patients may be asked for additional tests to be completed before a final assessment can be made.

4. Once patients are deemed suitable, a detailed schedule of their individual treatment protocol (including costs involved) will be provided.

ARE THERE ASSOCIATE SIDE EFFECTS?

Depending on the severity of disease present, symptoms may vary from no side effects to massive response to treatment. The associated art in applying this therapy involves a balance between three factors; the integrity of the patient's immune system, the severity of disease and the amount of therapy applied. Our present knowledge and our on-going scientific research ensure a tailoring of the treatment protocol to individual patient needs, which results in minimising any possible side effects.
OUR KNOWLEDGE AND RESEARCH
ENSURES INDIVIDUAL PATIENT TREATMENT